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Chronic kidney disease (CKD) is emerging as an important health problem due to the
increase number of CKD patients and the absence of an effective curative treatment.
Gremlin has been proposed as a novel therapeutic target for renal inflammatory
diseases, acting via Vascular Endothelial Growth Factor Receptor-2 (VEGFR2). Although
many evidences suggest that Gremlin could regulate renal fibrosis, the receptor involved
has not been yet clarified. Gremlin, as other TGF-β superfamily members, regulates
tubular epithelial to mesenchymal transition (EMT) and, therefore, could contribute
to renal fibrosis. In cultured tubular epithelial cells Gremlin binding to VEGFR2 is
linked to proinflammatory responses. Now, we have found out that in these cells
VEGFR2 is also involved in the profibrotic actions of Gremlin. VEGFR2 blockade by
a pharmacological kinase inhibitor or gene silencing diminished Gremlin-mediated gene
upregulation of profibrotic factors and restored changes in EMT-related genes. Moreover,
VEGFR2 inhibition blocked EMT phenotypic changes and dampened the rate of wound
healing in response to Gremlin. The role of VEGFR2 in experimental fibrosis was
evaluated in experimental unilateral ureteral obstruction. VEFGR2 inhibition diminished
the upregulation of profibrotic genes and EMT changes, as well as the accumulation of
extracellular matrix proteins, such as fibronectin and collagens in the obstructed kidneys.
Notch pathway activation participates in renal damage progression by regulating cell
growth/proliferation, regeneration and inflammation. In cultured tubular epithelial cells,
Notch inhibition markedly downregulated Gremlin-induced EMT changes and wound
healing speed. These results show that Gremlin regulates the EMT process via VEGFR2
and Notch pathway activation, suggesting that the Gremlin/VEGFR2 axis could be a
potential therapeutic target for CKD.
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INTRODUCTION
Chronic kidney disease (CKD) is a devastating disease that
affects 5–7% of the worldwide population and is a strong
forecaster of end-stage renal disease, cardiovascular morbidity,
and mortality (Sanchez-Niño et al., 2017). The elevated incidence
of obesity, diabetes and aging will greatly increase the number
of CKD patients in a near future. Regardless of the underlying
etiology, most renal diseases progress to permanent loss of
kidney function caused by progressive and irreversible nephron
loss and reduced regenerative capacity. CKD progression is
characterized by sustained inflammation (Anders, 2014) and
excessive accumulation of extracellular matrix (ECM) in the
kidney, leading to tubulointerstitial fibrosis that is associated to
renal function loss and end stage renal disease (Cortinovis et al.,
2016). The current therapeutic armamentarium for CKD only
slows disease progression, and novel therapeutic strategies are
needed. Intensive research has focused on finding novel potential
therapeutic targets for CKD, based on different approaches
from anti-inflammatory treatments to novel epigenetic drugs
(Duffield, 2014; Ruiz-Andres et al., 2016; Liu et al., 2018).
A current hypothesis is that the re-emergence of developmental
programs could participate in the pathogenesis of CKD and,
therefore, their blockade could exert protective effects (Roxburgh
et al., 2006). Among developmental genes, Gremlin has a
potential relevance as a therapeutic target (Lappin et al., 2002;
Mezzano et al., 2018).
Gremlin is a member of the DAN family of secreted
Bone Morphogenetic Proteins (BMPs) antagonists, contains a
cysteine-rich region and a cysteine knot motif responsible for
BMP binding, whose structure is shared by members of the
transforming growth factor beta (TGF-β) superfamily (Topol
et al., 2000; Mezzano et al., 2018). Earlier studies demonstrate
an important role of Gremlin in development, including
nephrogenesis, acting as a BMP antagonist (Merino et al., 1999;
Khokha et al., 2003; Michos et al., 2004). More recently, Gremlin
has been suggested as an important promoter of fibrosis in
different pathological conditions including renal, liver, lung, and
myocardial diseases (Dolan et al., 2005; Carvajal et al., 2008;
Mueller et al., 2013; Brazil, 2015; Erdmann et al., 2015; Mezzano
et al., 2018). Moreover, in vitro studies have demonstrated direct
effects of Gremlin in the regulation of profibrotic-related events
(Zode et al., 2009; Li et al., 2012; Rodrigues-Diez et al., 2012;
Huang et al., 2013). However, the potential Gremlin receptor
involved in fibrotic processes has not been fully defined.
Renal fibrosis is a major hallmark of CKD, and finding an
anti-fibrotic therapy is an unmet need. During the past decade,
the origin of myofibroblasts, the primary source of ECM in
scar tissue formation, has been intensively investigated. Current
data strongly suggest that in the kidney these myofibroblasts
may arise from a number of sources such as activation of tissue
fibroblasts, migration of circulating mesenchymal progenitors
or cell transitions, such as epithelial-to-mesenchymal transition
(EMT) or endothelial-to-mesenchymal transition (EndoMT)
(Zeisberg and Neilson, 2009; Duffield, 2014; Lovisa et al.,
2015; Liu et al., 2018). Interestingly Gremlin can induce EMT
of tubular epithelial cells and cancer cells (Li et al., 2012;
Rodrigues-Diez et al., 2012; Rodrigues-Diez et al., 2014), and can
activate other renal cells, including fibroblasts and mesangial cells
to increase the production of ECM proteins, such as collagens
(Rodrigues-Diez et al., 2012; Huang et al., 2013). However, the
receptor involved in Gremlin-induced fibrosis and EMT has not
been found out yet. Some studies suggest that Gremlin regulates
fibrosis by its BMP antagonist activity (Myllärniemi et al., 2008;
Staloch et al., 2015), whereas many other studies have observed
cellular actions of Gremlin independently of BMP antagonism
(Mezzano et al., 2018). Recently, the vascular endothelial growth
factor receptor 2 (VEGFR2) has been described as a Gremlin
receptor in endothelial and tubular epithelial cells, showing
some differences to canonical ligands in binding affinity and
downstream responses (Mitola et al., 2010; Corsini et al., 2014;
Lavoz et al., 2015; Mezzano et al., 2018). We have recently
described that Gremlin activates VEGFR2 signaling pathway in
the murine kidney, mainly on tubular epithelial cells, and this
is linked to the induction of an acute inflammatory response
(Lavoz et al., 2015). Interestingly, activation of VEGFR2 signaling
and re-expression of Gremlin in tubular epithelial cells has been
observed in several human nephropathies (Lavoz et al., 2015),
suggesting that the Gremlin/VEGFR2 axis could be involved in
CKD progression.
Notch signaling is an evolutionarily conserved pathway
involved in cell fate control during development, stem cell
self-renewal and postnatal tissue differentiation (Siebel and
Lendahl, 2017). This pathway is one of the most relevant
mechanisms regulating EMT in many cell types, including
carcinogenesis (Takebe et al., 2015). Levels of some Notch
pathway components have been proposed as biomarkers of renal
disease progression in human CKD and many preclinical studies
have suggested that Notch inhibition could be a therapeutic
option for renal diseases, by modulating, cell proliferation,
inflammation and EMT (Bielesz et al., 2010; Murea et al., 2010;
Sharma et al., 2011; Marquez-Exposito et al., 2018). We have
previously described that Gremlin activates Notch signaling
in the kidney leading into an acute inflammatory responses
(Lavoz et al., 2018), however, the role of this pathway in
Gremlin-induced EMT remains unstudied.
According to this background, we have investigated the
potential role of VEGFR2 in the regulation of Gremlin-induced
EMT in cultured tubular epithelial cells, and its role in renal
fibrosis, testing the effects of VEGFR2 blockade in experimental
renal fibrosis.
MATERIALS AND METHODS
Ethics Statement
All animal procedures were performed according to the
guidelines of animal research in the European Community and
with prior approval by the Ethics Committee of the Health
Research of the IIS-Fundación Jiménez Díaz.
Experimental Model of Renal Fibrosis
The model of unilateral ureteral obstruction (UUO) was
performed in male C57BL/6 mice under isoflurane-induced
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anesthesia. The left ureter was ligated with silk (5/0) at two
locations and cut between ligatures to prevent urinary tract
infection (obstructed kidney), as described (Lavoz et al., 2015)
and mice were studied after 5 days. To examine the VEGFR2
pathway, some animals were treated daily with the VEGFR2
kinase inhibitor SU5416 (i.p; 0.1 mg per day, Vichem, Budapest,
Hungary). To study the Notch pathway, some animals were
treated daily with the Notch inhibitor DAPT (a γ-secretase
inhibitor; i.p; 0.1 mg per day, Calbiochem). Both treatments were
started 1 day before UUO surgery (n = 8 mice per group). At
the time of sacrifice, animals were anesthetized with 5 mg/kg
xylazine (Rompun, Bayer AG) and 35 mg/kg ketamine (Ketolar,
Pfizer) and the kidneys were perfused in situ with cold saline
before removal. A piece of the kidney (2/3) was fixed, embedded
in paraffin, and used for immunohistochemistry, and the rest was
snap-frozen in liquid nitrogen for renal cortex RNA and protein
studies. In both models, studies compared the contralateral and
obstructed kidney in each mouse. In addition, a control group
of sham-operated mice showed the same results as contralateral
kidneys (data not shown).
Paraffin-embedded kidney sections were stained using
standard histology procedures. Immunostaining was carried
out in 3 µm thick tissue sections. Renal fibrosis was evaluated
by Sirius Red staining. Samples were mounted in non-aqueous
medium DPX new (Merck-Millipore) and examined by a Nikon
Eclipse E400 microscope. For quantification, the percentage
stained area out of the total area was calculated in five randomly
chosen fields (×200 magnification) using Image-Pro Plus
software (Media Cybernetics, Washington) and results were
expressed as fold-change over control.
Cell Culture Studies
Human renal proximal tubular epithelial cells (HK2 cell line,
ATCC CRL-2190) were grown in RPMI 1640 medium with 10%
heat-inactivated fetal bovine serum (FBS), 2 mM glutamine,
100 U/ml penicillin, 100 µg/ml streptomycin, 5 µg/ml Insulin
Transferrin Selenium (ITS) and 36 ng/ml hydrocortisone
in 5% CO2 at 37◦C. All the in vitro studies were done
in HK2 cell line (limitation of the study). At confluence,
cells were growth-arrested in serum-free medium for 24 h
before the experiments. Cells were cultured in six-well plates
and stimulated with vehicle or recombinant human Gremlin
(PeproTech, 10 ng/mL) for 24 (gene expression) or 48 h
(protein levels) in serum-free medium. In some experiments,
cells were preincubated for 1 h with VEGFR2 kinase inhibitor
SU5416 (5 µM; Vichem, Budapest, Hungary), or DAPT
(30 nM, Calbiochem). DMSO, used as solvent, as well as
SU5416 and DAPT alone had no effect on cell viability, gene
and protein expression (data not shown). Cells were used
for protein or RNA studies. Fibronectin was measured in
supernatants (cell-conditioned media) and in total protein extract
(cell-associated fraction).
Cell Transfection and Gene Silencing
Gene silencing in cultured cells was performed using either a
predesigned siRNA corresponding to the human KDR/VEGFR2
cDNA sequence (s7822; Ambion) or a non-specific control siRNA
(Ambion). Subconfluent HK2 cells were transfected for 24 h with
LipofectamineTM RNAiMAX Reagent (Invitrogen) according to
the manufacturer’s guidelines. Then, cells were incubated in
serum-free medium for 24 h before the experiments. Some
cells were stimulated with Gremlin or vehicle for different time
intervals.
Wound Healing
For wound healing assays, a single scrape wound was made with
a p20 pipette tip on a monolayer of cultured HK2 cells, and two
pictures per well were taken at this time point (t = 0) using an
inverted microscope (Leica DMI3000 B). Wounded cells were
preincubated 1 h with treatments (SU5416: 5 µM or DAPT:
30 nM) and later stimulated with Gremlin (10 ng/mL) or TGF-β1
(1 ng/mL). Seventy-two hours later two pictures were taken again
in the same point as at t = 0 and the gap area was measured using
the Image-Pro Plus software (Media Cybernetics, Washington).
Data are expressed as mean percentage of wound healing± SEM.
Protein Studies
Proteins were obtained from cells or mouse kidneys using
lysis buffer (50 mmol/l Tris–HCl, 150 mol/l NaCl, 2 mmol/l
EDTA, 2 mmol/l EGTA, 0.2% Triton X-100, 0.3% IGEPAL,
10 µl/ml proteinase inhibitor cocktail, 0.2 mmol/l PMSF, and
0.2 mmol/l orthovanadate). Protein levels were quantified
using a PierceTM BCA protein assay kit (Thermo Scientific,
Rockford, IL, United States). For Western blotting, cell protein
extracts (20–25 µg/lane) or cell supernatants (25–30 µl/lane)
were separated on 6–12% polyacrylamide-SDS gels under
reducing conditions. Samples were then transferred onto
PVDF membranes (Bio-Rad, Spain), blocked with TBS/5%
non-fat milk/0.05% Tween-20, and incubated overnight
at 4◦C with the corresponding primary antibodies. After
washing, membranes were incubated with the appropriate
HRP (horseradish peroxidase)-conjugated secondary antibody
(Amersham Biosciences) and developed using an ECL kit
(Amersham Biosciences). The quality of proteins and efficacy
of protein transfer were evaluated by Red Ponceau staining
(data not shown). The loading control for soluble proteins (cell
supernatants) was Red Ponceau staining and the albumin band
(67 kDa) was used for quantification of the loading control.
Digital chemiluminescence images were taken by LAS 4000
(GEHealthcare) and quantified by Quantity One R© software.
The following primary antibodies were employed [dilution]:
α-smooth muscle actin (α-SMA) ([1:1000], Sigma), E-cadherin
([1:500], CST), Fibronectin ([1:5000]; BD Pharmingen),
panCytokeratin ([1:500], Sigma), Vimentin (E-5) ([1:1000];
Santa Cruz, sc-373717), α-tubulin ([1:5000]; Sigma) and
GAPDH ([1:5000]; Chemicon International).
Immunofluorescence Staining of EMT
Markers
To determine EMT changes, specific EMT markers were assessed
by immunofluorescence in control and Gremlin-stimulated cells
for 72 h. Cells were fixed with 4% PFA, permeabilized with
triton X-100 (0.2%), blocked with 4% BSA in PBS and incubated
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with the following primary antibodies [dilution]: Vimentin
([1:200], Santa Cruz, sc-373717), panCytokeratin (C11) ([1:200];
Santa Cruz, sc-8018) and α-SMA ([1:200], Sigma). Secondary
antibodies were Alexa Fluor R©-488 conjugated antibody ([1/200]
A21206, Invitrogen) and Alexa Fluor R©-633 conjugated antibody
([1/200]; A21206, Invitrogen). Nuclei were stained with 1 µg/ml
DAPI (Sigma-Aldrich) as control of equal cell density. Absence
of primary antibody was used as negative control. Samples were
mounted in ProLongTM Gold Antifade Reagent (Invitrogen by
Thermo Fisher Scientific) and examined by a Leica TCS SP5
confocal microscope.
Gene Expression Studies
RNA from cells or renal tissue (pulverized in a metallic
chamber) was isolated with TriPure reagent (Roche). cDNA
was synthesized by a High Capacity cDNA Archive kit (Applied
Biosystems) using 2 µg of total RNA primed with random
hexamer primers following the manufacturer’s instructions.
Next, quantitative gene expression analysis was performed
by real-time PCR on an AB7500 fast real-time PCR system
(Applied Biosystems) using fluorogenic TaqMan MGB
probes and primers designed by Assay-on-DemandTM gene
expression products. Human assays IDs were: E-CADHERIN
(CDH1), Hs01023895_m1; TFG-b 1 (TGFB1), Hs00998133_m1;
CTGF, Hs00170014_m1, FIBRONECTIN, Hs00401006_m1,
and VIMENTIN: Hs00185584_m1. Mouse assays IDs were:
fibronectin (Fn1), Mm01256744_m1; type I collagen (Col1a2),
Mm00483888_m1; tgf-β1 (tgfb1), Mm01178820_m1; pai-1
(Serpine), Mm00435858_m1. Data were normalized to human
GAPDH Hs02786624_g1, or mouse gapdh: Mm99999915_g1.
The mRNA copy numbers were calculated for each sample by the
instrument software using Ct value (“arithmetic fit point analysis
for the lightcycler”). Results were expressed in copy numbers,
calculated relative to unstimulated cells after normalization
against GAPDH.
Statistical Analysis
Results throughout the text are expressed as mean± SEM of fold
increase over control. Differences between groups were assessed
by Student t (cells) and Mann-Whitney (mice) tests. Statistical
significance was assumed when a null hypothesis could be
rejected at p < 0.05. Statistical analysis was performed using the
SPSS statistical software, version 16.0, Chicago, IL, United States.
RESULTS
Gremlin via VEGFR2 Regulates the
Expression of Many Genes Involved in
Fibrosis in Cultured Tubular Epithelial
Cells
Gremlin binds to VEGFR2 present in tubular epithelial cells
in vivo and in vitro (Lavoz et al., 2015). Previous studies in
cultured tubular epithelial cells have shown Gremlin regulates
several profibrotic factors and ECM components (Li et al., 2012;
Rodrigues-Diez et al., 2012, 2014), however, the role of VEGFR2
in these processes had not been investigated. Preincubation of
cultured human tubular epithelial cells (HK2 cell line) with the
pharmacological VEGFR2 kinase inhibitor SU5416 diminished
Gremlin-mediated gene upregulation of profibrotic factors,
including TGF-β1 and CTGF, and ECM components, such as
fibronectin, evaluated by real time PCR (Figure 1A). Moreover,
Gremlin-induced production of soluble fibronectin was blocked
by treatment with the VEGFR2 kinase inhibitor, as determined
by western blot (Figure 1B). Cell-associated fibronectin showed
the same tendency but not statistical differences were found
(Figure 1C).
The involvement of VEGFR2 on profibrotic gene regulation
was further evaluated by gene silencing. HK2 cells were
transfected with a siRNA against VEGFR2 or its corresponding
scrambled control siRNA, and then stimulated with Gremlin for
24 h. In VEGFR2-silenced cells, Gremlin did not increase the
gene expression of profibrotic factors and ECM related proteins,
whereas in untransfected cells or in cells transfected with a
control siRNA, Gremlin increased all those genes (Figure 1D).
Gremlin Induces EMT in Cultured Tubular
Epithelial Cells via VEGFR2 Signaling
Activation
An early study observed that during the transdifferentiation of
tubular epithelial cells to fibroblasts, one of the most upregulated
genes was Gremlin (Murphy et al., 2002). Latter, we described
that Gremlin, both by stimulation with a recombinant Gremlin
protein or by transfection with a Gremlin expression vector,
could induce EMT in cultured human tubular epithelial cells
(Rodrigues-Diez et al., 2012, 2014). Now, we have investigated
whether VEGFR2 behaves as a Gremlin receptor involved in EMT
regulation. EMT is initiated by the disruption of intercellular
junctions resulting in a loss of their apical-basolateral polarity,
and the acquisition of a front-back polarity. In HK2 cells,
stimulation with Gremlin (10 ng/ml) decreased the expression
of proteins that keep basolateral polarity, such as the epithelial
marker Cytokeratin, as shown by confocal microscopy, that was
restored in cells pretreated with the VEGFR2 inhibitor SU5416
(Figure 2A). EMT was also characterized by de novo synthesis of
mesenchymal markers, such as α-SMA and vimentin (Zeisberg
and Neilson, 2009). Gremlin induced vimentin expression
associated to a change in cell phenotype from the typical
cobblestone pattern of an epithelial monolayer to myofibroblast
morphology, which was prevented by SU5416 (Figure 2A).
Changes in EMT-related proteins were also confirmed by
western blot. Gremlin decreased the protein levels of Cytokeratin
and E-cadherin, essential proteins for the structural integrity
of the renal epithelium, and increased vimentin and α-SMA
levels, which were prevented by VEGFR2 inhibition in the
case of e-cadherin, a-SMA and Vimentin (Figure 2B). To
further demonstrate the role of VEGFR2 in the regulation of
Gremlin-induced EMT process, gene-silencing experiments were
done. The evaluation of changes in the representative marker
of activated myofibroblasts α-SMA by confocal microscopy
clearly showed that stimulation with Gremlin in VEGFR2
gene silenced cells, was not able to induce the phenotype
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FIGURE 1 | Gremlin via VEGFR2 regulates profibrotic factors and ECM components in cultured human tubular epithelial cells. Cells (HK2 cell line) were preincubated
with the VEGFR2 kinase inhibitor SU5416 (5 µM) or vehicle before stimulation with Gremlin (10 ng/ml). (A) Gene expression was evaluated 24 h after Gremlin
stimulation. Total cell RNA was isolated to assess mRNA levels of TGF-β, CTGF, and FIBRONECTIN by quantitative real-time PCR. (B) Effect of VEGFR2 blockade on
Gremlin-induced ECM protein production was evaluated by quantifying soluble fibronectin levels by western blot, after 48 h of incubation. Figures show a
representative experiment of soluble (B) and cell associated (C) Fibronectin (upper panel) and quantification (lower panel). Results are expressed as mean ± SEM of
six independent experiments. ∗p < 0.05 vs. control, #p < 0.05 vs. Gremlin. (D) VEGFR2 gene silencing blocked Gremlin-induced gene upregulation of matrix-related
factors. HK2 cells were transfected with a siRNA against VEGFR2 or siRNA scrambled as described in Materials and Methods. Then, cells were stimulated or not
with 10 ng/mL Gremlin for 24 h. Data are expressed as mean ± SEM of five independent experiments. ∗p < 0.05 vs. control untransfected; #p < 0.05 vs. untreated
control siRNA-transfected cells; $p < 0.05 vs. Gremlin-treated control siRNA-transfected cells; &p < 0.05 vs. Gremlin-treated untransfected cells.
changes and there was lower staining intensity compared to
Gremlin-treated control siRNA transfected cells (Figure 3A).
Additionally, SU5416 pretreatment or VEGFR2 gene silencing
also modulated Gremlin-induced changes at the gene expression
level, as observed for E-Cadherin and vimentin mRNA levels
(Figures 2C, 3B).
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FIGURE 2 | Gremlin via VEGFR2 induces EMT in tubular epithelial cells. (A) Cells (HK2 cell line) were preincubated with the VEGFR2 kinase inhibitor SU5416 (5 µM)
or vehicle before stimulation with Gremlin (10 ng/ml) for 72 h. By confocal microscopy changes in epithelial phenotype and EMT-markers were evaluated. Vimentin is
shown in green and Cytokeratin in red. Figure shows a representative experiment of two done by confocal microscopy. (B) Changes in EMT-related markers were
quantified by western blot Gremlin diminished the levels of the epithelial markers E-Cadherin and Cytokeratin and increased the expression of mesenchymal
markers, α-SMA and vimentin. All these changes were prevented by VEGFR2 inhibition. (C) Gene expression was evaluated 24 h after Gremlin stimulation. Total cell
RNA was isolated to assess mRNA levels of VIMENTIN, and E-CADHERIN by quantitative real-time PCR. Figure shows mean ± SEM of six independent
experiments. ∗p < 0.05 vs. control; #p < 0.05 vs. Gremlin.
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FIGURE 3 | VEGFR2 gene silencing blocked Gremlin-induced EMT related changes in tubular epithelial cells. Sub-confluents HK2 cells were transfected with a
siRNA against VEGFR2 or siRNA scrambled during 48 h. Then, cells were stimulated or not with 10 ng/mL Gremlin for 72 h. (A) Changes in the representative
marker of activated myofibroblasts α-SMA was evaluated by confocal microscopy. To see cell density the nuclear marker DAPI was used. Figure shows a
representative experiment of two done by confocal microscopy. (B) Gene expression was evaluated in silenced cells 24 h after Gremlin stimulation. Total cell RNA
was isolated to assess mRNA levels of VIMENTIN, and E-CADHERIN by quantitative real-time PCR. Data are expressed as mean ± SEM of five independent
experiments. ∗p < 0.05 vs. control untransfected; #p < 0.05 vs. untreated control siRNA-transfected cells; $p < 0.05 vs. Gremlin-treated control siRNA-transfected
cells; &p < 0.05 vs. Gremlin-treated untransfected cells.
Gremlin via VEGFR2 Modulates Wound
Healing in Cultured Tubular Epithelial
Cells
Wound healing assays showed that Gremlin (10 ng/ml) increased
the speed of epithelial cells invading the scar region compared
to untreated cells, evaluated after 72 h (Figure 4). This response
was similar to that observed in response to TGF-β1 stimulation
(10 ng/ml), used as a positive control. The VEGFR2 kinase
inhibitor SU5416 significantly diminished the percentage of
wound healing induced by Gremlin (Figure 4).
VEGFR2 Blockade Inhibits Experimental
Renal Fibrosis
Gremlin administration in the murine kidney induces
an acute inflammatory response, however, there was no
increased ECM deposition in the kidney (Lavoz et al.,
2018). Therefore, to evaluate the potential in vivo effects of
Gremlin on renal fibrosis the UUO model was employed.
This model is characterized by tubulo-interstitial fibrosis,
observed as early as 5 days followed renal injury (Ucero
et al., 2014). Moreover, in obstructed kidneys, Gremlin is
increased and is associated to VEGFR2 activation (Lavoz et al.,
2015). VEGFR2 kinase inhibition in obstructed kidneys
prevented the increase in the expression of profibrotic
(TGF-β1 and PAI-1) and matrix-related (fibronectin and
type I collagen) genes that was observed in untreated
obstructed kidneys (Figure 5A) and prevented the increase
in Fibronectin protein (Figure 5B). The effect of VEGFR2
inhibition on renal fibrosis was further evaluated by Sirius
red staining (Figure 5D). This technique disclosed a clear
diminution of collagen deposition in mice treated with
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FIGURE 4 | Gremlin via VEGFR2 regulates cells migration and proliferation in wound healing experiments. A monolayer of epithelial cells (HK2 cell line) was used as
starting point. A single scrape wound was made in all cells and then they were stimulated with Gremlin (10 ng/ml) in the presence or absence of VEGFR2 kinase
inhibitor SU5416 (5 µM, preincubated 1 h before). After 72 h, cells were evaluated under inverted microscopy. (A) Representative images of wound healing
experiments and (B) their quantification. Results are expressed as mean ± SEM of four independent experiments, done by duplicate. ∗p < 0.05 vs. control;
#p < 0.05 vs. Gremlin.
VEGFR2 inhibition as compared to untreated obstructed
kidneys (Figure 5C). These data show that inhibition of
VEGFR2 signaling ameliorates renal fibrosis and suggest
that blockade of Gremlin/VEGFR2 could be responsible
for downregulation of profibrotic events in injured
kidneys.
Blockade of Notch Pathway Activation
Inhibited Experimental Renal Fibrosis
In some experimental models, Notch blockade ameliorates
renal damage, mainly by inhibiting fibroblast proliferation
and therefore, decreasing fibrosis (Bielesz et al., 2010;
Marquez-Exposito et al., 2018). Treatment of obstructed
mice with the γ-secretase inhibitor DAPT, an inhibitor
of Notch activation, prevented the increase in renal
profibrotic gene expression (Figure 5A), fibronectin levels
(Figure 5B), and collagen deposition (Figures 5C,D)
to levels similar to contralateral kidneys. These data
confirms and extend previous observations (Bielesz et al.,
2010).
Notch Pathway Activation Is Involved in
Gremlin-Induced EMT
Finally, we further investigated whether the Notch pathway
could be directly involved in Gremlin profibrotic responses.
Preincubation with the γ-secretase inhibitor DAPT diminished
Gremlin-induced changes in profibrotic gene expression and
ECM components (Figure 6). Changes caused by Gremlin in
the cell morphology and in EMT-related genes and proteins
levels were prevented by DAPT (Figure 7). Moreover, the
effects of Gremlin on wound healing speed were also inhibited
by DAPT (Figure 8). DAPT alone did not show effect on
wound healing when compared to control (Pazos et al.,
2017).
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FIGURE 5 | VEGFR2 kinase inhibition ameliorates experimental renal fibrosis in the model of unilateral ureteral obstruction. Mice were treated with SU5416 (i.p;
0.1 mg per day) starting 24 h before UUO surgery and were studied after 5 days. To evaluate the role of the Notch pathway, some mice were also treated with the
Notch inhibitor DAPT (i.p; 0.1 mg per day). (A) RNA was obtained from total renal extracts and tgf-b1, pai-1, fibronectin, and type I collagen mRNA levels were
determined by RT-qPCR. (B) Fibronectin protein levels were evaluated in total renal extracts by Western blotting. Levels of α-tubulin were used as a loading control.
Figure shows several representative mice from each group and the quantification of the Western blot data. (C,D) Collagen deposition was evaluated in
paraffin-embedded sections by Sirius Red staining, quantification assessed the stained area as a proportion of total area. (D) Figures show a representative mouse
from each group. Magnification 200×, and (C) the quantification. Data are expressed as mean ± SEM of 6–8 animals per group. ∗p < 0.05 vs. control; #p < 0.05
vs. UUO 5 days.
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FIGURE 6 | Gremlin via Notch pathway regulates profibrotic factors and ECM components in cultured human tubular epithelial cells. Cells (HK2 cell line) were
preincubated with DAPT (30 nM) before stimulation with Gremlin (10 ng/ml). (A) Gene expression levels were evaluated 24 h after Gremlin stimulation. Total cell RNA
was isolated to assess mRNA levels by RT-qPCR. Fibronectin levels were evaluated after 48 h in cell supernatants (B) and in total protein extracts (C).
A representative western blot experiment is shown in upper panel and quantification in the lower panel. ∗p < 0.05 vs. control, #p < 0.05 vs. Gremlin.
DISCUSSION
In this paper we have described that in cultured tubular epithelial
cells, VEGFR2 is the receptor involved in the regulation of
the EMT program and of profibrotic-related genes in response
to Gremlin. In human progressive CKD, Gremlin upregulation
was associated to activation of VEGFR2 signaling, mainly in
tubular epithelial cells (Lavoz et al., 2015). Moreover, Gremlin
overexpression was found in areas of increased ECM deposition
(Dolan et al., 2005; Mezzano et al., 2018), suggesting that this
factor can participate in renal fibrosis. Our in vivo studies show
anti-fibrotic effects of VEGFR2 inhibition in experimental kidney
fibrosis, suggesting that the Gremlin/VEGFR2 axis could be a
potential therapeutic target in renal disease.
In the kidney, Gremlin binds to VEGFR2 in tubular epithelial
cells activating this receptor and subsequent downstream
signaling pathways linked to regulation of renal inflammation
(Lavoz et al., 2015, 2018). Now, our in vitro data in cultured
tubular epithelial cells show that Gremlin via VEGFR2 activation
regulates several gene programs to control profibrotic, ECM and
EMT related factors. In other cell types Gremlin actions are also
mediated by VEGFR2. In endothelial cells, Gremlin binds to
VEGFR2 and activates this pathway regulating cell proliferation,
migration, and angiogenesis (Shibuya and Claesson-Welsh, 2006;
Mitola et al., 2010; Corsini et al., 2014). In skin keratinocytes and
fibroblasts, Gremlin via VEGFR2 activates NF-E2-related factor 2
(NERF2) signaling and cell growth (Ji et al., 2016), and in retinal
epithelial cells via mTOR regulates proliferation and migration
(Liu et al., 2017). However, the receptor involved in Gremlin
responses in other renal cells had not been investigated. In this
sense, podocytes seem not to express VEGFR2 (Li et al., 2013).
Our in vitro data suggest that VEGFR2 could be the receptor
involved in Gremlin-mediated fibrotic responses in the kidney,
but future research is needed in other kidney cell types beyond
tubular cells.
Epithelial to mesenchymal transition is a cell reprogramming
process in which epithelial cells acquire a mesenchymal
phenotype. The contribution of tubular EMT to renal fibrosis
is a matter of intense debate (LeBleu et al., 2013; Duffield,
2014; Lovisa et al., 2015; Liu et al., 2018). EMT is characterized
by the loss of the epithelial properties of tubular epithelial
cells, including permeability and polarity, which may result in
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FIGURE 7 | Gremlin via Notch pathway induces EMT in cultured human tubular epithelial cells. Cells (HK2 cell line) were preincubated with DAPT (30 nM) before
stimulation with Gremlin (10 ng/ml). Changes in EMT-related markers were assessed by confocal microscopy (A) or western blot (B). Please, note that the pictures of
e-cadherin, α-sma and their corresponding loading control (GAPDH) are the same images as shown in the Figure 2B but, in this case, Gremlin + DAPT point is
included in the fourth lane. Results are expressed as mean ± SEM of five independent experiments. All changes induced by Gremlin were prevented by Notch
inhibition. Figure (A) shows a representative experiment out of two performed by confocal microscopy and (B) shows representative images of western blot and
quantification. (C) Gene expression levels were evaluated 24 h after Gremlin stimulation. Total cell RNA was isolated to assess mRNA levels by RT-qPCR. Data are
expressed as mean ± SEM of six independent experiments. ∗p < 0.05 vs. control; #p < 0.05 vs. Gremlin.
decreased viability and contribute to renal injury (Duffield, 2014;
Lovisa et al., 2015; Liu et al., 2018). Although in experimental
and human CKD the number of myofibroblasts of tubular
origin could be scarce, and it is not relevant to the total
increase in collagen deposition, partial EMT is an initial step
in renal damage and an important potential therapeutic target.
In cultured tubular epithelial cells, we have found that VEGFR2
blockade, by the pharmacological inhibitor SU5416 or by gene
silencing, inhibited the EMT program induced by Gremlin
Therefore, Gremlin/VEGFR2 blockade could exert protective
effects in renal injury by restoring or preventing the loss of
epithelial integrity.
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FIGURE 8 | Effect of Notch inhibition on Gremlin-induced changes in wound
healing assays. A monolayer of epithelial cells (HK2 cell line) was used as
starting point. A single scrape wound was made. Then cells were
preincubated with DAPT (30 nM) or vehicle before stimulation with Gremlin
(10 ng/ml). After 72 h, cells were evaluated under an inverted microscopy.
(A) Representative images of wound healing experiments and (B) their
quantification. Results are expressed as mean ± SEM of four independent
experiments, performed by duplicate. ∗p < 0.05 vs. control; #p < 0.05 vs.
Gremlin.
Epithelial to mesenchymal transition also participates in
wound healing, malignant transformation and embryogenesis. In
our study, we show that VEGFR2 is involved in Gremlin-induced
wound healing in tubular epithelial cells. Gremlin induces EMT
changes in other cell types, including airway epithelial cells
(McCormack et al., 2013). In cancer cell lines, Gremlin besides
EMT, also causes cell migration, invasion, and proliferation
through BMP and VEGFR2-independent mechanisms (Kim
et al., 2012; Yin et al., 2017; Mezzano et al., 2018). Future studies
are needed to define the receptor involved in Gremlin-induced
EMT in proliferative disorders.
Earliest studies showed that Gremlin could acts as a
BMPs antagonist, mainly involved in embryogenesis, including
kidney development (Merino et al., 1999; Khokha et al.,
2003; Michos et al., 2004). However, the role of Gremlin
as BMPs antagonists in other physiological and pathological
conditions is controversial. Gremlin-induced inflammatory
responses are BMP-independent, as described in endothelial
and tubular epithelial cells, and are linked to activation of
several transcription factors, NF-κB and Notch-1 (Corsini et al.,
2014; Lavoz et al., 2015, 2018). Gremlin affinity for BMPs
can vary between cells and pathological conditions, explaining
the divergent results published. In isolated pancreatic stellate
cells Gremlin acting as a BMP antagonist abolished BMP2’s
suppression effects on TGF-β-induced collagen expression, by
its binding to BMP2 and subsequent blockade of Smad1/5
phosphorylation, and therefore inhibiting BMP2 anti-fibrotic
effects (Staloch et al., 2015). BMP7 have proven to be
capable of reversing renal fibrosis in mice, EMT and in vitro
profibrotic effects of TGF-β and Gremlin (Zeisberg et al.,
2003; Weiskirchen and Meurer, 2013). In this regard, there
is a complex relationship between BMPs and TGF-β signaling
in the regulation of homeostasis and tissue fibrosis. Novel
data indicate that Gremlin is another important player in
this context. In cultured renal cells Gremlin is a downstream
mediator of TGF-β profibrotic responses, including EMT of
tubular epithelial cells (Rodrigues-Diez et al., 2012). In vitro
Gremlin activates TGF-β/Smad pathway in tubular epithelial
cells and in podocytes (Li et al., 2013; Rodrigues-Diez et al.,
2014). Additionally, TGF-β blockade inhibited Gremlin-induced
EMT (Rodrigues-Diez et al., 2014). All these data show a
close interrelation between TGF-β and Gremlin, acting both as
profibrotic factors.
Many experimental evidences suggest that Gremlin could
be an important promoter of fibrosis in different pathologies,
including liver fibrosis, lung diseases (particularly pulmonary
hypertension and idiopathic pulmonary fibrosis), myocardial
fibrosis, and chronic pancreatitis (Khokha et al., 2003; Mueller
et al., 2013; Brazil, 2015; Mezzano et al., 2018). In several
human renal diseases, Gremlin was found overexpressed, mainly
in areas of tubulointerstitial fibrosis (Murphy et al., 2002;
Dolan et al., 2005; Carvajal et al., 2008), suggesting that
Gremlin could be involved in the fibrotic process during CKD.
Several studies have demonstrated a direct fibrogenic effect of
Gremlin in renal cells. In mesangial cells, Gremlin increased
cell proliferation and ECM accumulation via ERK (Huang
et al., 2013) and in renal fibroblasts Gremlin increased ECM
production (Rodrigues-Diez et al., 2012). Accordingly, we have
recently observed that in a model of Gremlin-induced renal
damage there was an upregulation of fibrotic related genes,
including TGF-β1, which were blocked by VEGFR2 kinase
inhibition (Lavoz et al., 2018). However, no renal fibrosis
was observed. Now, we have found out that experimental
renal fibrosis was prevented by VEGFR2 blockade. In the
UUO model, treatment with a VEGFR2 kinase inhibitor
significantly prevented the renal overexpression of profibrotic
factors and accumulation of key ECM proteins such as collagen.
Interestingly, blocking VEGFR2 by circulating soluble receptor
ectodomains, diminished fibrosis and capillary rarefaction in
UUO (Lin et al., 2011). In that study, VEGFR2 blockade also
blocked pericyte PDGFRβ activation, and pericyte differentiation
and proliferation (Lin et al., 2011), thus blocking another source
of scar-producing myofibroblasts. Unfortunately, that study did
not assess Gremlin levels nor the role of Gremlin/VEGFR2
responses on endothelial cells. In mice, Gremlin blockade
diminished ECM accumulation, as observed in streptozotocin-
induced diabetes in knockout mice heterozygous for Grem1
(Roxburgh et al., 2009) and by Gremlin gene silencing (Zhang
et al., 2010). Moreover, transgenic mice overexpressing Grem-1
specifically in tubular cells presented increased susceptibility
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to renal damage, induced by streptozotocin or folic acid
administration (Droguett et al., 2014; Marchant et al., 2015).
Accordingly, specific deletion of Grem-1 in tubular cells
diminished renal fibrosis in folic acid-induced damage in
mice (Church et al., 2017). These data show that inhibition
of VEGFR2 signaling ameliorates renal fibrosis and suggest
that Gremlin/VEGFR2 blockade could be responsible of the
downregulation of profibrotic events, suggesting a novel
anti-fibrotic therapy for CKD.
Activation of the Notch pathway participates in renal damage
progression, but the precise mechanisms are not fully elucidated
(Marquez-Exposito et al., 2018). In some experimental models of
renal damage, including acute kidney injury models, such as folic
acid administration in mice, Notch blockade by pharmacological
inhibitors or soluble Notch ligands ameliorates renal damage,
mainly by inhibiting fibroblast proliferation and therefore
decreasing fibrosis (Bielesz et al., 2010; Murea et al., 2010; Sharma
et al., 2011; Marquez-Exposito et al., 2018). More recently,
anti-inflammatory properties of Notch inhibition have been
described in experimental renal damage (Lavoz et al., 2018).
In a previous study in the UUO model, authors demonstrated
that a γ-secretase inhibitor downregulated gene expression of
fibronectin and type I Collagen (Bielesz et al., 2010). Here, we
have extended these data at the protein level showing that DAPT
prevented the increase of profibrotic factors, including TGF-β1,
and the renal accumulation of collagen and fibronectin in a UUO
model. Notch is involved in EMT in carcinogenesis (Takebe et al.,
2015; De Francesco et al., 2018). In cultured tubular epithelial
cells, we found that DAPT diminished Gremlin-induced EMT
changes, confirming the role of the Notch pathway in EMT
regulation.
Chronic progressive kidney fibrosis remains an unresolved
challenge. Irrespective of the underlying cause, CKD is linked
to the development of tubulo-interstitial fibrosis. Our data show
that blockade of Gremlin-mediated VEGFR2/Notch activation
ameliorates fibrotic events and EMT processes, suggesting that
Gremlin might be a fibrosis driver through VEGFR2 and Notch
pathway, and a possible therapeutic target.
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